| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-2448-20MG | Orlistat | 20mg | $63.00 | |
| GBM-2448-100MG | Orlistat | 100mg | $105.00 |
| Bioassays Specification | |
| Bio-Activity | DAG lipase-a inhibitor |
| Chemical Name | N-formyl-L-leucine (1S)-10[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester |
| Function / Pharmacology | A lipase inhibitor which blocks the biosynthesis of 2-AG by inhibition of DAG lipase-α1. Inhibits pancreatic lipase and other lipases but not PLA22. Inhibits fatty acid synthase and displays antitumor activity3. Prevents fat absorption in the gut and is a clinically useful antiobesity agent4. |
| CAS# | 96829-58-2 |
| MW | 495.75 |
| Molecular Formula | C29H53NO5 |
| Solubility | Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 50 mg/ml). |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Bisogno et al. (2006), Development of the first potent and specific inhibitors of endocannabinoid biosynthesis; Biochim. Biophys. Acta, 1761 205 2) Hadvary et al. (1991), The lipase inhibitor tetrahydrolipstatin bind covalently to the putative active site serine of pancreatic lipase; J. Biol. Chem., 266 2021 3) Kridel et al. (2004), Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity; Cancer Res., 64 2070 4) Ballinger & Peikin (2002), Orlistat: it’s current status as an anti-obesity drug; Eur. J. Pharmacol., 440 109 |
| Antibody Specification | |
| Alternate Names | Ro18-0647; Tetrahydrolipstatin (-) |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | DAG lipase-a inhibitor |
| Chemical Name | N-formyl-L-leucine (1S)-10[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester |
| Function / Pharmacology | A lipase inhibitor which blocks the biosynthesis of 2-AG by inhibition of DAG lipase-α1. Inhibits pancreatic lipase and other lipases but not PLA22. Inhibits fatty acid synthase and displays antitumor activity3. Prevents fat absorption in the gut and is a clinically useful antiobesity agent4. |
| CAS# | 96829-58-2 |
| MW | 495.75 |
| Molecular Formula | C29H53NO5 |
| Solubility | Soluble in DMSO (up to 50 mg/ml) or in Ethanol (up to 50 mg/ml). |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Bisogno et al. (2006), Development of the first potent and specific inhibitors of endocannabinoid biosynthesis; Biochim. Biophys. Acta, 1761 205 2) Hadvary et al. (1991), The lipase inhibitor tetrahydrolipstatin bind covalently to the putative active site serine of pancreatic lipase; J. Biol. Chem., 266 2021 3) Kridel et al. (2004), Orlistat is a novel inhibitor of fatty acid synthase with antitumor activity; Cancer Res., 64 2070 4) Ballinger & Peikin (2002), Orlistat: it’s current status as an anti-obesity drug; Eur. J. Pharmacol., 440 109 |
| Antibody Specification | |
| Alternate Names | Ro18-0647; Tetrahydrolipstatin (-) |
| Protein Specification | |
| Purity | >98% |
